TARSUS PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
TARSUS PHARMACEUTICALS, INC. (TARS) had Debt Securities, Available-for-sale, Amortized Cost of $245.65 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $245.65M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $286.84M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $233.25M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $288.82M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $245.65M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $286.84M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $233.25M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $288.82M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $284.46M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $232.04M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $196.38M 10-K · filed 2026-02-23 |
| 2024-09-30 | $140.40M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $142.66M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $105.94M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.50M 10-K · filed 2025-02-25 |
| 2023-09-30 | $20.20M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $71.48M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $135.29M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $145.44M 10-K · filed 2024-02-27 |
| 2022-09-30 | $57.09M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |